Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group nucleosomal binding domain 2 pseudogene 30 (HMGN2P30) is a processed pseudogene in the human genome that shares high sequence similarity to the functional HMGN2 gene, which encodes a chromatin-associated protein involved in nucleosome binding[3][5][2]. Pseudogenes like HMGN2P30 do not encode functional proteins due to mutations, frameshifts, or premature stop codons preventing translation[2][9]. While traditionally considered nonfunctional "junk DNA," emerging evidence suggests some pseudogenes may participate in the regulation of gene expression by acting as decoys for regulatory RNAs or by modulating transcript stability[7][9]. However, there are no direct therapeutic, biomarker, or safety implications for HMGN2P30, and it is not considered a druggable or disease-associated target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group nucleosomal binding domain 2 pseudogene 30 (HMGN2P30).